Literature DB >> 9854569

Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma?

I D Hay1, C S Grant, E J Bergstralh, G B Thompson, J A van Heerden, J R Goellner.   

Abstract

BACKGROUND: Controversy continues regarding the optimal extent of primary thyroid resection in most patients with papillary thyroid carcinoma (PTC), who are at minimal risk of cause-specific mortality (CSM). This study was designed to compare CSM and recurrence rates after either unilateral lobectomy (UL) or bilateral lobar resection (BLR) in patients with PTC considered low risk by AMES criteria.
METHODS: Outcome was studied in 1685 patients initially treated during 1940 through 1991 and followed for up to 54 postoperative years (mean, 18 years). One thousand six hundred fifty-six patients (98%) had complete primary tumor resection; 634 (38%) had involvement of regional nodes. One hundred ninety-five patients (12%) had UL; BLR accounted for 1468 (near-total 60%; total thyroidectomy 18%).
RESULTS: Thirty-year rates for CSM and distant metastasis were 2% and 3%, respectively. Twenty-year rates for local recurrence and nodal metastasis were 4% and 8%, respectively. There were no significant differences in CSM or distant metastasis rates between UL and BLR (P > .2). After UL, 20-year rates for local recurrence and nodal metastasis were 14% and 19%, significantly higher (P = .0001) than the 2% and 6% rates seen after BLR.
CONCLUSIONS: UL was not associated with higher CSM rates, but it was associated with a significantly higher risk of locoregional recurrence. Thus BLR probably represents a preferable initial surgical approach to patients with low-risk PTC.

Entities:  

Mesh:

Year:  1998        PMID: 9854569

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  51 in total

1.  Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.

Authors:  Ian D Hay; William M McConahey; John R Goellner
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

2.  Pediatric thyroid cancers: an Indian perspective.

Authors:  Devendra A Chaukar; Abhishek D Vaidya
Journal:  Indian J Surg Oncol       Date:  2012-02-16

Review 3.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

4.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

Review 5.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

Review 6.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

7.  Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy?

Authors:  Cho Rok Lee; Haiyoung Son; Sohee Lee; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Woong Youn Chung; Cheong Soo Park
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

8.  Impact of Extent of Surgery on Tumor Recurrence and Survival for Papillary Thyroid Cancer Patients.

Authors:  Rajshri M Gartland; Carrie C Lubitz
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

9.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

10.  FNA of misclassified primary malignant neoplasms of the thyroid: Impact on clinical management.

Authors:  Sejal S Shah; William C Faquin; Roberto Izquierdo; Kamal K Khurana
Journal:  Cytojournal       Date:  2009-01-19       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.